5-Amino-1MQ vs BAM15
Both have positive mouse metabolic data but different mechanisms (NNMT inhibition vs mitochondrial uncoupling) and neither has established human efficacy/safety.
| Attribute | 5-Amino-1MQ | BAM15 |
|---|---|---|
| Human evidence | No established therapeutic human trial evidence was identified in this review. | No therapeutic human trial evidence was identified. |
| Research focus | Obesity, adiposity and metabolic research | Obesity, insulin resistance and metabolic research |
| Regulatory status | No FDA/EMA-approved therapeutic product identified. | No FDA/EMA-approved medicine identified. |
| Route / formulation | 5-Amino-1MQ is a small-molecule research compound, not a peptide. | This is not a peptide; commercial oral products have no established clinical validation. |
Why these are compared
These compounds appear in the experimental metabolic compounds evidence landscape, but they are not interchangeable. 5-Amino-1MQ is small-molecule nnmt inhibitor studied in obesity, adiposity and metabolic research; BAM15 is small-molecule mitochondrial protonophore/uncoupler studied in obesity, insulin resistance and metabolic research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
5-Amino-1MQ: Preclinical only — positive mouse metabolic data, no human therapeutic evidence.
BAM15: Preclinical only — compelling mouse metabolic data, no human therapeutic evidence.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No human head-to-head evidence; both preclinical. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty. For any compound with little or no established human exposure, published human safety and efficacy data would also materially change the evidence picture.